What is Tasso?
Tasso is a pioneering medical technology firm dedicated to revolutionizing the patient experience through the decentralization of diagnostic testing. By enabling individuals to perform clinical-grade blood collection and testing from the comfort of their homes, Tasso effectively removes traditional barriers to healthcare access. This model not only improves patient compliance and comfort but also provides healthcare providers with timely, actionable data to inform clinical decision-making. As the industry shifts toward value-based care, Tasso's platform serves as a critical infrastructure component for remote patient monitoring and longitudinal health tracking.
How much funding has Tasso raised?
Tasso has raised a total of $125.4M across 4 funding rounds:
Grant
$2.3M
Other Financing Round
$6.1M
Series A
$17M
Series B
$100M
Grant (2014): $2.3M, investors not publicly disclosed
Other Financing Round (2019): $6.1M led by Vertical Venture Partners
Series A (2020): $17M, investors not publicly disclosed
Series B (2021): $100M featuring Senvest Capital, SVB Innovation Fund, D. E. SHAW, InCube, and RA Capital Management
Key Investors in Tasso
Senvest Capital
Incorporated in 1968 and located in Montreal, Canada, Senvest Capital operates as a holding company with interests in investment management and direct investing in public securities and private investments.
D. E. SHAW
Founded in 1988, D. E. Shaw is an asset management company. D. E. Shaw specializes in quantitative investing and is headquartered out of New York, New York.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools.
What's next for Tasso?
With the recent influx of capital, Tasso is well-positioned to accelerate its commercial expansion and deepen its integration into existing healthcare delivery networks. The strategic focus will likely center on scaling manufacturing capabilities to meet rising demand and expanding the diagnostic menu available through its proprietary collection devices. Furthermore, the company is expected to leverage these resources to strengthen its clinical validation efforts, ensuring that its home-based testing solutions meet the rigorous standards required for widespread adoption by health systems and pharmaceutical partners. As Tasso matures, the focus will shift toward long-term sustainability and the establishment of a new standard for patient-led diagnostic workflows.
See full Tasso company page
